XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENTS
 9 Months Ended
Sep. 30, 2024
SEGMENTS [Abstract]  
SEGMENTS
11.
SEGMENTS


The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.  The Company’s ADMA BioManufacturing operating segment reflects the Company’s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.  The Plasma Collection Centers operating segment consists of  ten plasma collection facilities located throughout the United States, all of which are operational, collecting plasma and currently hold FDA licenses. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. While not considered an operating segment, the Corporate information included in the tables below consists of certain unallocated general and administrative overhead expenses and interest expense on the Company’s senior debt (see Note 7). The Company’s CODM is its President and Chief Executive Officer. For the Company’s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended September 30, 2024
  
    ADMA    
Plasma Collection
             
(in thousands)  
BioManufacturing
    
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
113,088
    
$
6,715
    
$
36
    
$
119,839
  
                                 
Cost of product revenue
    
52,731
      
7,449
      
-
      
60,180
  
                                 
Income (loss) from operations
    
48,347
      
(1,755
)
    
(6,954
)
    
39,638
  
                                 
Interest and other expense, net
    
(54
)
    
-
   
(2,835
)
    
(2,889
)
                                 
Income (loss) before taxes
    
48,293
      
(1,755
)
    
(9,789
)
    
36,749
  

                               
Depreciation and amortization expense
   
1,138
      
802
      
-
      
1,940
  
Total assets
     266,456       33,191       90,971       390,618  

Three Months Ended September 30, 2023
  
    ADMA    
Plasma Collection
             
(in thousands)  
BioManufacturing
    
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
66,567
    
$
672
    
$
36
    
$
67,275
  
                                 
Cost of product revenue
    
41,734
      
888
      
-
      
42,622
  
                                 
Income (loss) from operations
    
15,017
      
(683
)
    
(5,649
)
    
8,685
                                 
Interest and other (expense) income, net
    
(141
)
    
-
      
(5,979
)
    
(6,120
)
                                 
Income (loss) before taxes
    
14,876
      
(683
)
    
(11,628
)
    
2,565
                                 
Depreciation and amortization expense
    
1,282
      
811
      
-
      
2,093
  
Total assets     262,554       35,622       50,821       348,997  

Nine Months Ended September 30, 2024
  
    ADMA    
Plasma Collection
             
(in thousands)  
BioManufacturing
    
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
299,385
    
$
9,413
    
$
107
    
$
308,905
  
                                 
Cost of product revenue
     142,193
      
10,492
      
-
      
152,685
  
                                 
Income (loss) from operations
     123,756      
(4,047
)
    
(19,049
)
    
100,660
  
                                 
Interest and other expense, net
     (95 )    
(4
)
    
(9,560
)
    
(9,659
)
                                 
Income (loss) before taxes
    
123,661
      
(4,051
)
    
(28,609
)
    
91,001
  
                                 
Capital expenditures
     5,364       105       -       5,469  
Depreciation and amortization expense
    
3,686
      
2,415
      
-
      
6,101
  

Nine Months Ended September 30, 2023
  
    ADMA    
Plasma Collection
             
(in thousands)  
BioManufacturing
    
Centers
    
Corporate
    
Consolidated
  
                         
Revenues
  
$
175,905
    
$
8,299
    
$
107
    
$
184,311
  
                                 
Cost of product revenue
    
118,708
      
7,747
      
-
      
126,455
  
                                 
Income (loss) from operations
    
26,577
      
(3,029
)
    
(16,149
)
    
7,399
                                 
Interest and other expense, net
    
(170
)
    
-
      
(17,823
)
    
(17,993
)
                                 
Income (loss) before taxes
    
26,407
      
(3,029
)
    
(33,972
)
    
(10,594
)
                                 
Capital expenditures
     1,768       1,806       -       3,574  
Depreciation and amortization expense
    
3,857
      
2,366
      
-
      
6,223
  

Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:
   
Three Months Ended September 30,
    
Nine Months Ended September 30,
  
(in thousands)  
2024
   
2023
   
2024
   
2023
 
United States
  
$
114,748
    
$
64,618
    
$
295,465
    
$
173,920
  
International
    
5,091
      
2,657
      
13,440
      
10,391
  
Total revenues
  
$
119,839
    
$
67,275
    
$
308,905
    
$
184,311